EU/USA BSE "Drugs" Row Moves Towards Settlement

13 November 1997

The first steps towards avoiding a trade war between the USA and theEuropean Union in the wake of the bovine spongiform encephalopathy scare have been made at the Transatlantic Business Dialogue meeting in Rome.

The USA had threatened to take action under the World Trade Organization against EU plans to ban imports of meat by-products such as tallow and gelatine from January, which the USA says would hit $4.5 billion worth of US exports of drugs containing such products. It is estimated that up to 85% of drugs produced in tablet form contain these products. The USA says it has no history of BSE, but the EU has claimed that the USA has had cases of the sheep disease scrapie, believed to be the originator of BSE.

However, at the meeting, US Under-Secretary of State Stuart Eizenstat said that the EU had persuaded him that it meant to settle the dispute, adding that the meeting had been "a catalyst for change."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight